Foreign Firms Shift Chinese Operations Toward Innovation Hubs

Multinational corporations are increasingly transitioning their Chinese operations from simple manufacturing bases into innovation hubs by integrating local research and development capabilities. This strategic shift aims to accelerate decision-making and leverage China's evolving healthcare landscape to enhance global competitiveness.

In Tianjin, GE HealthCare opened its Magnetic Resonance Eastern Hemisphere Headquarters R&D Center, marking the company's only system-level MR imaging research base outside the United States. The French healthcare company Stago established its only production site outside Europe in Tianjin and has shifted toward local R&D. Similarly, the Danish pharmaceutical firm Novo Nordisk announced a 200 million yuan investment to expand pen-injector assembly capacity in the city.

These investments align with China's 15th Five-Year Plan and the Healthy China Initiative, both of which prioritize biomedicine. The Ministry of Commerce reported that nearly 4,000 foreign-invested firms increased their investment in China during the first five months of 2026.